MindImmune Therapeutics Secures $12.4M in Series A Funding

MindImmune Therapeutics, Inc. is at the forefront of discovering mechanisms of neuroinflammation that may be targeted for breakthrough therapeutics for brain disease. With such ground-breaking research, it’s no surprise that the company has raised $12.4 million in Series A financing.

Their research is focused on the science around blocking aberrant immune system activity. This activity is an effector of nervous system disease, and blocking it may have positive impacts around the cause of symptoms and progression in many devastating neurodegenerative and neuropsychiatric disorders.

Collectively, the co-founders bring over a century of experience in drug discovery. The founders are experts in neuropharmacology, neuroscience, and pharmaceutical drug discovery and development.

MindImmune’s scientists are bridging knowledge of both the nervous and immune systems in an effort to discover previously unrecognized immune effector mechanisms underlying brain disease. To support this endeavor, the company has decided to actualize their knowledge in the form of a facile drug discovery engine. Their flagship program may herald a breakthrough therapeutic for Alzheimer’s disease.

Alzheimer’s disease is a chronic inflammatory condition wherein the immune system becomes inappropriately activated. Then the inflammatory response fails to resolve this activation. This inappropriate immune response usually manifests as innate immune first responder cells infiltrating into the brain, where these cells cause damage to synapses.  This synaptic damage underlies both the cognitive symptoms and the relentless progression of Alzheimer’s disease.

MindImmune has identified the key innate immune cells that infiltrate the brain in these instances. Armed with this knowledge, the company began developing an antibody therapy to block this infiltration and ameliorate the synaptic attack.

Investors participating in the Series A funding round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors. The funding will go towards supporting the company’s lead program in preclinical development, targeting Alzheimer’s disease as the primary indication.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts